Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)

On the August 26 Mad Money episode, a listener inquired whether it was time to sell or if Eton Pharmaceuticals (ETON) held further potential. Responding, Jim Cramer advised taking some profits. He acknowledged the biotech's exciting run and its status as a winner, but suggested withdrawing a portion of gains while allowing the rest to continue growing.

Eton Pharmaceuticals' recent price surge, from $30 to above $60, was fueled by impressive fundamentals. In Q2, the company reported record product sales of $37.6 million, a 99% year-over-year increase that surpassed expectations by $10.5 million. This growth was driven by the successful relaunch of HEMANGEOL and continued expansion in its pediatric endocrinology portfolio, including DESMODA and INCRELEX.

Eton's financial performance also improved, shifting from a net loss to a notable GAAP net income, with adjusted earnings per share reaching $0.43, exceeding Wall Street forecasts. However, the company faced potential challenges, including a slight compression in adjusted gross margin to 73% due to negative gross margins on Increlex international shipments.

Additionally, insider sales by management, including the CEO and Chief Business Officer, raised concerns. Despite these issues, institutional interest in Eton has grown, with the stock now held by 28 hedge funds compared to 20 in the previous quarter. Insiders have also been trimming their holdings. Cramer's advice is not to abandon Eton but to secure gains amid the company's strong performance.